Niflumic Acid
Especificaciones
4394-00-7Número CAS
224-516-2Número CE
2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acidNombre IUPAC
C13H9F3N2O2Fórmula química
282.22 g/molPeso molecular
niflumic acid; 4394-00-7; Acido niflumico; Acide niflumique; Niflugel; UP 83; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; Acidum niflumicum; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; DTXSID1023368; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; UP-83; 4U5MP5IUD8; NSC-758196; DTXCID903368; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; Acid, Niflumic; 2-((3-(trifluoromethyl)phenyl)amino)pyridine-3-carboxylic acid; 2-[[3-(trifluoromethyl)phenyl]amino]pyridine-3-carboxylic acid; RefChem:389149; M01AX02; M02AA17; 224-516-2; Landruma; Nifluril; Forenol; Nifluminic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; 2-((3-(Trifluoromethyl)phenyl)amino)nicotinic acid; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-; Lopac-N-0630; MFCD00010569; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; Niflumic acid (INN); 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; MLS000069713; NFL; 3-Pyridinecarboxylic acid, 2-((3-(trifluoromethyl)phenyl)amino)-; 2-(3-(Trifluoromethyl)phenylamino)nicotinic acid; Niflumic Acid-d5; NCGC00015724-10; Niflumate; SMR000058199; CAS-4394-00-7; M02156; NIFLUMIC ACID [INN]; Acide niflumique [French]; Acido niflumico [Italian]; Niflamol; Niflugel (TN); SC 1332; CCRIS 5740; SR-01000000231; EINECS 224-516-2; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; UNII-4U5MP5IUD8; BRN 0489360; niflumic-acid; ni-flumic acid; Niflumic acid [INN:BAN:DCF]; Actol, analgesic; 2-[[3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; Niflumic acid CRS; Prestwick_890; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; 1794811-58-7; Spectrum_001353; 1td7; Opera_ID_1746; Prestwick0_000255; Prestwick1_000255; Prestwick2_000255; Prestwick3_000255; Spectrum2_000794; Spectrum3_001485; Spectrum4_000043; Spectrum5_001216; Niflumic acid (Standard); Niflumic acid (Hit 16); N 0630; NIFLUMIC ACID [MI]; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; CBiol_001828; Lopac0_000845; SCHEMBL24706; BSPBio_000070; BSPBio_001393; BSPBio_003069; KBioGR_000113; KBioGR_000505; KBioSS_000113; KBioSS_001833; 5-22-13-00598 (Beilstein Handbook Reference); MLS001076327; CHEMBL63323; DivK1c_000277; SPECTRUM1502015; SPBio_000928; SPBio_002289; NIFLUMIC ACID [MART.]; BPBio1_000078; GTPL2439; orb1310379; NIFLUMIC ACID [WHO-DD]; SCHEMBL29364001; SCHEMBL29373503; BDBM85507; CHEBI:34888; HMS500N19; HY-B0493R; KBio1_000277; KBio2_000113; KBio2_001833; KBio2_002681; KBio2_004401; KBio2_005249; KBio2_006969; KBio3_000225; KBio3_000226; KBio3_002569; MSK7198; NINDS_000277; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; Bio1_000114; Bio1_000603; Bio1_001092; Bio2_000113; Bio2_000593; GLXC-07398; HMS1361F15; HMS1568D12; HMS1791F15; HMS1921D12; HMS1989F15; HMS2090D19; HMS2095D12; HMS2234F11; HMS3262J11; HMS3374H01; HMS3402F15; HMS3649A08; HMS3656P14; HMS3712D12; HMS3885I03; HMS5081O04; Nicotinic acid, 2-(alpha,alpha,alpha-trifluoro-m-toluidino)-; Pharmakon1600-01502015; HY-B0493; NIFLUMIC ACID [EP IMPURITY]; NSC_4488; UWC81158; Tox21_110206; Tox21_500845; BBL003619; CCG-40157; DL-457; EBC-03797; Nicotinic acid, 2-(.alpha.,.alpha.,.alpha.-trifluoro-m-toluidino)-; NIFLUMIC ACID [EP MONOGRAPH]; NSC758196; s3018; SBB001146; STK803109; AKOS000519590; Tox21_110206_1; AC-2652; DB04552; FN26214; GS-3202; LP00845; NSC 758196; SDCCGSBI-0050821.P004; IDI1_000277; IDI1_033863; NCGC00015724-01; NCGC00015724-02; NCGC00015724-03; NCGC00015724-04; NCGC00015724-05; NCGC00015724-06; NCGC00015724-07; NCGC00015724-08; NCGC00015724-09; NCGC00015724-11; NCGC00015724-12; NCGC00015724-13; NCGC00015724-14; NCGC00015724-17; NCGC00015724-29; NCGC00023636-03; NCGC00023636-04; NCGC00023636-05; NCGC00023636-06; NCGC00023636-07; NCGC00023636-08; NCGC00023636-09; NCGC00261530-01; ST013871; SY002411; CAS_4394-00-7; SBI-0050821.P003; 2(3'-trifluormethylanilino)-nicotinic acid; AB00052255; EU-0100845; N3322; NS00010059; SW197011-3; EN300-17360; D08275; H10042; AB00052255-17; AB00052255_18; AB00052255_19; 2-((3-(Trifluoromethyl)phenyl)amino)nicotinicacid; Q304285; SR-01000000231-2; SR-01000000231-5; SR-01000000231-6; BRD-K98763141-001-04-3; BRD-K98763141-001-06-8; BRD-K98763141-001-17-5; BRD-K98763141-001-29-0; BRD-K98763141-001-30-8; SR-01000000231-11; Z56922127; 2-[3-(Trifluoromethyl)anilino]-3-pyridinecarboxylic acid; Niflumic acid, European Pharmacopoeia (EP) Reference Standard; Niflumique (acide)Sinónimos
